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Published guidelines differ in emphasis regarding choices 
of pharmacologic agents but both groups suggest ac- 
etaminophen/paracetamol as first line therapy. Some, but not all, 
studies suggest that acetaminophen/paracetamol is efficacious 
in the short-term management of OA pain. Efficacy has gen- 
erally been found to be lower than that of NSAIDs/coxibs but 
cost effectiveness analysis reveals that acetaminophen domi- 
nates NSAIDs/coxibs in terms of cost per gastrointestinal event 
averted. 
The role of opioid analgesics in the treatment of osteoarthritis i  
less straightforward. The ACR guidelines uggest use of tramadol 
as the initial central acting analgesic to use in patients with con- 
traindications to NSAIDs/coxibs, such as renal insufficiency, or 
who were unresponsive to NSAIDs/coxibs while EULAR guide- 
lines make no specific recommendation for one agent over oth- 
ers. Both groups cite the paucity of data on the use of opiates in 
OA. A limited number of short-term studies suggest that a variety 
of agents may be of benefit in treating moderate to severe pain 
but physicians and patients remain concerned about adverse ef- 
fects, tolerance and dependence. 
The American Pain Society has issued clinical practice guide- 
lines (Simon Let  al Guideline for the Management of Pain in Os- 
teoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis, 
2 nd Ed. 2002; Glenview, IL:American Pain Society) on the man- 
agement of pain in OA. These guidelines unequivocally recom- 
mend the use of opioids when other medications and nonphar- 
macologic interventions produce inadequate relief of moderate to 
severe pain and the pain affects the patient's quality of life. Guid- 
ance is provided for initial dose and dose escalation in addition 
to special precautions regarding potential side effects associated 
with particular agents. 
Therapies from complementary and alternative medicine includ- 
ing glucosamine, chondroitin, avocado soybean unsaponifiables 
and acupuncture may be useful adjuncts in pain management as 
well. 
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GLUCOSAMINE SULPHATE IN THE MANAGEMENT OF 
OSTEOARTHRITIS:  THE EUROPEAN PERSPECTIVE 
Jean-Yves Reginster 
Two long-term (three years) placebo-controlled, randomised tri- 
als have concluded that the daily intake of 1.500 mg of crystalline 
glucosamine sulphate fully prevented the joint loss observed in 
placebo-treated patients, presenting with grade I1-111 knee os- 
teoarthritis. In these studies, whereas symptoms, assessed by 
Womac scores and Lequesne index worsened in the placebo 
group, they improved, after treatment with glucosamine sulphate. 
These studies were criticised because of the X-Rays method- 
ology for assessment of joint space narrowing (anteroposterior 
radiograph of the knee in full extension). It was subsequently 
demonstrated that in this particular setting, pain improvement 
was not a confounding factor for the assessment of the struc- 
tural properties of glucosamine sulphate. In a long-term follow-up 
evaluation, occurring in average 5 years after the end of the tri- 
als and treatment discontinuation, a 48% decrease in risk of knee 
surgery in the former glucosamine sulphate group was reported. 
In a subset of patients, who had, at that time, a radiographic as- 
sessment, it was observed that those previously on glucosamine 
sulphate had halved joint space narrowing over the entire obser- 
vational period. Those patients, also showed improved Womac 
function and total scores, had better quality of life-score and spent 
50% less for drugs, visits and procedure for osteoarthritis. A clin- 
ically relevant and significant difference of 10-15% in favor of glu- 
cosamine sulphate was observed in the proportion of patients 
reaching the Minimal Clinically Important Improvement (MCII) 
and Patients Acceptable Symptoms Status (PASS) for Womac 
pain and function scores showing the clinical relevance of the dif- 
ference in clinical evolution observed between the glucosamine 
and the placebo groups, notwithstanding the mild severity char- 
acteristics of the patients enrolled in the two long-term studies. In 
conclusion, in the European experience, glucosamine sulphate 
was associated with a clinically relevant improvement in symp- 
toms and with a significant reduction in joint space narrowing that 
translated, five years later, in a reduction of the need for surgery. 
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PANEL DISCUSSION - NUTRAPHARMACEUTICALS  IN 
THE TREATMENT OF OA. CHONDROITIN SULPHATE-  
THE EUROPEAN TRIALS 
Eric Vignon 
Chondroitin sulphate (CS) is marketed and reimbursed as a 
symptomatic medical treatment of OA in several European coun- 
tries. Clinical benefit of CS has been demonstrated in the short 
term but effects of the treatment in the long term are less known. 
A one year symptomatic trial in 120 patients with knee OA with 
an intermittent CS treatment of 800 mg per day demonstrated that 
improvement inpain and Lequesne index progressively increased 
with time and remained significantly better than in the placebo 
(PBO) group at completion of the trial. Minimum joint space width 
(JSW) was measured in standing anteroposterior radiographs ob- 
tained at entry and completion of the study in a number of knees. 
The mean decrease in JSW was 0.32 mm in the PBO group and 
nil in the CS group (p<0.05). 
A 2 year structure trial using a posteroanterior radiograph of the 
knee in flexion was conducted in 300 patients treated with CS 
(800 mg daily) or PBO. Decrease in JSW was minimal in the 
PBO group (0.14mm) but was nil in the CS group (P<0.05). Clin- 
ical benefit (WOMAC scores) of CS was mild and not statistically 
different between groups. 
A 3 year structure trial using fluoroscopically assited Lyon schuss 
radiographs and a daily CS dose of 1000 mg has been conducted 
in 620 patients with knee OA. Data are not yet available. 
